The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

ZORYVE's rapid sales growth positions Arcutis Biotherapeutics as a strong buy with profitability expected in 12 months. Read ...

The Californian company earlier announced the US Food and Drug Administration’s (FDA) acceptance of a supplemental New Drug ...

If approved, the cream would be marketed under the brand name Zoryve. Zoryve ® Cream 0.15% is currently indicated for the topical treatment of mild to moderate atopic dermatitis in adult and ...

Arcutis Biotherapeutics is advancing in alopecia areata and atopic dermatitis with ZORYVE. Learn why ARQT stock offers growth ...

Arcutis Biotherapeutics (ARQT) announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 ...

One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate ...

ZORYVE cream - a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor in a once-daily cream formulation, approved in the United States for the treatment of plaque psoriasis and atopic ...

Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth ...

(RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT), on Wednesday, announced that its supplemental new drug application for ZORYVE cream 0.05 percent has been accepted for review by the FDA.

"Highlighting additional data from our clinical development program for ZORYVE foam in scalp and body psoriasis and ZORYVE cream in atopic dermatitis reinforces the strong need for well-tolerated ...